We serve Chemical Name:Calcium arsenite CAS:27152-57-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Calcium arsenite
CAS.NO:27152-57-4
Synonyms:Arsenous acid,calcium salt (2:3);ARSENIOUS ACID,CALCIUM SALT;tricalcium diarsorite;EINECS 248-266-9;Calcium arsenite (3:2);Calcium arsenite (Ca3As2O6);Monocalcium arsenite;Tricalcium diarsenite
Molecular Formula:As2Ca3O6
Molecular Weight:366.07400
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:138.36000
Exact Mass:365.70000
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1574
Packing Group:II
Contact us for information like Arsenous acid,calcium salt (2:3) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tricalcium diarsenite physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ARSENIOUS ACID,CALCIUM SALT Use and application,Monocalcium arsenite technical grade,usp/ep/jp grade.
Related News: “The most important thing to be considered while determining a CDMO competency is their technical knowledge along with adequate expertise to accomplish the drug development till commercial scaling. 6-(1-hydroxy-2-(4-(2-methylquinolin-5-yl)piperidin-1-yl)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one dihydrochloride manufacturers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 4-((5-hydroxy-13,24,33,43,54,63-hexaoxin-2-yl)oxy)-34,43-hexaoxidan-3-one suppliers “Alcami supported this product with supply constraints and successfully developed a capsule formulation for two dosage strengths,” she explains. “The formulations group performed studies at a micro-laboratory scale using a scientifically-based approach to identify a lead prototype. (+)-(S)-3-phenylpentan-1-ol vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 4-((5-hydroxy-13,24,33,43,54,63-hexaoxin-2-yl)oxy)-34,43-hexaoxidan-3-one suppliers “Alcami supported this product with supply constraints and successfully developed a capsule formulation for two dosage strengths,” she explains. “The formulations group performed studies at a micro-laboratory scale using a scientifically-based approach to identify a lead prototype. (+)-(S)-3-phenylpentan-1-ol vendor & factory.
